Clinical stage oncology company, Immuneering Corporation (Nasdaq: IMRX) has been granted Fast Track Designation by the FDA for its IMM-1-104, for the treatment of patients…
February 21, 2024
February 20, 2024
AI Companies Shaping Tomorrow: A Jetsons-Worthy Portfolio Selection
Artificial Intelligence or “AI” seems to be the new, hot two letter word on everybody’s lips. If you’re a CEO mentioning AI on an earnings…
February 20, 2024
Cybin Reports Positive Topline Results in Depression Study
Cybin Inc. (NYSE American: CYBN) has reported its unaudited financial results for its third quarter ended December 31, 2023 and highlighted positive Phase 2 topline…
February 20, 2024
Aytu BioPharma Reports Record Revenue from ADHD Asset
Aytu Biopharma (Nasdaq: AYTU) has announced its financial and operational results for the fiscal 2024 second quarter. The company’s ADHD Portfolio (Adzenys XR-ODT® and Cotempla…
February 13, 2024
Adverum Demonstrates “Sustained Disease Control” in Phase 2 Trial for Macular Degeneration
Adverum Biotechnologies (Nasdaq: ADVM) has reported positive preliminary safety and efficacy data from a Phase 2 trial in patients with wet age-related macular degeneration (AMD)…
Tonix Pharmaceuticals (Nasdaq: TNXP) is offering new hope to the 6 – 12 million Americans living with fibromyalgia with a potential new frontline treatment that…
February 09, 2024
Intelligent Bio Solutions Surges 238% on Strong Earnings
Shares in rapid test solutions company, Intelligent Bio Solutions (Nasdaq: INBS), surged nearly 240% in intraday trading on Friday after the company reported its financial…
February 09, 2024
AIM ImmunoTech Tackles Post-COVID Fatigue
AIM ImmunoTech (NYSE American: AIM) has reported positive topline results from a Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential…
Biodexa Pharmaceuticals (Nasdaq: BDRX) has provided survival updates from its clinical study of MTX110 in patients with recurrent glioblastoma (“rGBM”). Currently, no standard of care…
February 08, 2024
Microbot Medical Takes Step Towards Human Clinical Trial in US
Surgical robotics company, Microbot Medical (Nasdaq: MBOT) has taken an important step closer to initiating a pivotal human clinical trial in the United States with…
Clinical stage pharmaceutical company, Iterum Therapeutics (Nasdaq: ITRM) has announced positive topline results from its Phase 3 clinical trial comparing oral sulopenem to oral Augmentin®…
February 07, 2024
Lipocine Advances Postpartum Depression Candidate
Lipocine Inc. (Nasdaq: LPCN) has confirmed the dosing regimen for its upcoming New Drug Application (NDA)-enabling pivotal pharmacokinetic (PK) study of LPCN 1154, an oral…